{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001382","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2022-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.926696+00:00","generated_at":"2026-06-23T01:31:44.962996+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"USANA Q3 sales $233M (-15% YoY), EPS $0.78; slashes FY2022 guidance","bullets":["Net sales $233M, down 15% YoY ($274M); diluted EPS $0.78 vs $1.36, down 43%.","Active customers fell 18% to 474,000; Asia Pacific region sales down 17% constant currency.","FY2022 outlook cut: net sales $955-975M (prev. $1,015-1,065M); EPS $3.15-3.40 (prev. $3.85-4.45).","Operating cash flow $29M; cash $247M, debt-free; no share repurchases in quarter.","Management cites COVID disruptions in Asia, stronger USD headwind of ~$15M (6% of sales)."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001382","json":"https://secwatch.observer/filing/0001157523-22-001382.json","markdown":"https://secwatch.observer/filing/0001157523-22-001382.md","text":"https://secwatch.observer/filing/0001157523-22-001382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752322001382/0001157523-22-001382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752322001382/a52952545.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:31:44.962996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}